BioCrossroads adds Lilly, Indiana Biosciences Research Institute executives to Board of Directors
June 01, 2021
Indianapolis, Ind. – BioCrossroads announces that Adrienne Brown, vice president of US Diabetes at Eli Lilly and Company, and Alan Palkowitz, PhD, president and CEO of the Indiana Biosciences Research Institute (IBRI) have joined the board of directors.
Brown oversees the commercial efforts for Lilly USA’s largest business unit. Previously, as Business Unit Director – Lilly Japan, she served on the executive team and helped position Lilly Japan as a top-tier pharma company. During this time, she led the Diabetes Business Unit strategy, establishing Lilly as the industry leader in the diabetes market, delivering double-digit revenue growth for several consecutive years.
In Brown’s 17-year career at Lilly, she has directed multiple market-leading pharma brands and has held positions in sales, marketing and strategy. Her passion is to advance care and improve patient outcomes for people around the world.
Dr. Palkowitz has 30 years of experience in drug discovery and development in both industry and academia. In addition to his role at the IBRI, Dr. Palkowitz maintains his role at the Indiana University (IU) School of Medicine as a senior research professor of medicine, where he directs the IUSM-Purdue TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (TREAT-AD) Center. Dr. Palkowitz previously served as the vice president of Discovery Chemistry Research and Technologies at Eli Lilly and Company, where he worked for 28 years.
Additionally, Dr. Palkowitz has served on several prominent advisory committees, including most recently the National Institutes of Health's National Center for Advancing Translational Sciences Advisory Council and the National Academies of Sciences’ Board on Chemical Sciences and Technology.
“We are delighted to welcome Adrienne and Alan to our board and look forward to benefiting from their combined knowledge, capabilities and energy,” said Patty Martin, president and CEO for BioCrossroads. “Their extensive yet complementary experiences will be invaluable to BioCrossroads as we continue to ignite growth for Indiana’s life sciences industry.”